Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
about
Structural Insights into High Density Lipoprotein: Old Models and New FactsDouble Superhelix Model of High Density LipoproteinapoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.Activation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices.Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cellsAlteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL.Apolipoprotein A-I exerts bactericidal activity against Yersinia enterocolitica serotype O:3High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol.Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models.Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDLSignificance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL.Sequence-specific apolipoprotein A-I effects on lecithin:cholesterol acyltransferase activity.
P2860
Q26770434-0AA02AC4-DC43-45EC-AFE4-41FC35C3E05AQ27657720-1C667FBD-3458-4908-945D-E06439A80CD7Q33825134-365AEC2E-D96A-4863-BE5A-B52BBF5147B4Q33937174-7775CEB4-AD99-4132-889F-CAA0CD321BA5Q34624089-AD453FD1-B996-40B2-91A5-CF93CE015393Q35067300-5A885855-AE1E-41B5-B9D7-04DE1C43B34CQ35515462-33486821-838F-4EB9-B68D-95C6118855A7Q36607325-1057127C-435C-4E18-9703-A22212BC4A07Q37076007-78D09048-EE7E-4AEE-B656-E1F9317F59B5Q37305358-A70E79D3-F564-48E4-A520-9C7DD984000DQ37305361-0830F6B2-8972-4A28-953C-2FD39749FC32Q44923253-C6979A43-7A3B-4B14-82BC-18E76EBFE688
P2860
Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Naturally occurring and bioeng ...... rected by treatment with LCAT.
@en
type
label
Naturally occurring and bioeng ...... rected by treatment with LCAT.
@en
prefLabel
Naturally occurring and bioeng ...... rected by treatment with LCAT.
@en
P2093
P2860
P356
P1433
P1476
Naturally occurring and bioeng ...... rrected by treatment with LCAT
@en
P2093
Adelina Duka
Angeliki Chroni
Dimitris Kardassis
P2860
P304
P356
10.1042/BJ20070296
P407
P577
2007-08-01T00:00:00Z